Latest Endometriosis News

Page 1 of 3
Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
Ada Torres
30 Oct 2026
Proteomics International will take Promarker D and Promarker Eso nationwide through Healius from 26 October, extending its first commercial release beyond Western Australia and the Northern Territory. The tests will initially be offered privately at $495 and $997, while revenue remains too uncertain to forecast.
Victor Sage
Victor Sage
23 Oct 2026
Proteomics International has begun a controlled release of two Promarker diagnostic tests through Healius in Western Australia and the Northern Territory. National commercial sales are targeted for Q2 FY27, but uptake and revenue remain difficult to estimate at this early stage.
Ada Torres
Ada Torres
14 Sept 2026
Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.
Ada Torres
Ada Torres
13 Aug 2026
Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.
Ada Torres
Ada Torres
27 July 2026
Proteomics International has locked in a three-year exclusive distribution deal with Healius, leveraging its extensive pathology network to roll out its Promarker® diagnostic tests nationally from FY27.
Ada Torres
Ada Torres
22 July 2026
Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.
Ada Torres
Ada Torres
8 July 2026
Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.
Ada Torres
Ada Torres
28 Apr 2026
EVE Health Group has appointed Ben Rohr as CEO, shifting Damian Wood to focus on regulatory and clinical affairs, aiming to sharpen commercial execution amid ongoing product rollouts.
Ada Torres
Ada Torres
28 Apr 2026
Eve Health Group is advancing its proprietary reformulation platform with two fast-onset products launched under Australia's SAS-B pathway, targeting large underserved markets in women's and men's health. The company’s capital-light, partner-led model aims for rapid revenue growth post-ARTG registration.
Ada Torres
Ada Torres
26 Mar 2026
EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.
Ada Torres
Ada Torres
20 Mar 2026
EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.
Ada Torres
Ada Torres
18 Mar 2026

Browse the archive

Full archive